Use of 3-hydroxy-3-methylgutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
US6894058B1 · kind B1 · utility
4Cited by
10References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 1, 2000 |
| Grant date | May 17, 2005 |
| Priority date | — |
| Expiry date | Feb 1, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a new use of a statin drug in the improvement of diabetic neuropathy, specifically in improving nerve conduction velocity and nerve blood flow in patients suffering diabetes, in particular to pharmaceutical combinations of the statin drug and other agents known to improve diabetic neuropathy such as an aldose reductase inhibitor (ARI), an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II (AII) antagonist which combinations are useful in the prevention and treatment of the complications of diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.